When you think of the early warning signs of diabetes, skin problems likely aren't the first thing to come to mind. But our ...

The dosing interval for ixekizumab may be extended in some patients with plaque psoriasis, and switching between biologics may also be considered.

They are most common in adults with fair skin over the age of 50, and particularly for those who have spent a lot of time in ...

We hear from Mike Lewis, professor of oral medicine at Cardiff University, who explains how oral lichen planus manifests.

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

The global burden of chronic kidney disease (CKD) is rising, with more than 800 million people affected worldwide. Vascular diseases in patients with CKD are unique and grouped as uremic vascular ...

HONG KONG, China I April 18, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal ...

“These data underscore the promise of next-generation therapies and the potential for icotrokinra to offer adolescents with moderate to severe plaque psoriasis the unique combination of a favorable ...

So you might get a persistent scaly patch, lesions, bumps or rough spots, and they tend to be in very sun-exposed areas." If you notice a change in your skin that doesn't seem usual, speak to your GP.

Icotrokinra had more significant improvements than placebo for multiple skin clearance measures following 16 weeks of treatment for plaque psoriasis in adolescents and adults. Icotrokinra is ...

In the Phase III ICONIC-LEAD trial, 75% of adolescents with moderate-to-severe plaque psoriasis treated with icotrokinra achieved completely clear skin by week 24. Results from the Phase III ...

1 "Adolescents living with moderate to severe plaque psoriasis shouldn't have to wait for effective treatments options that have the potential to deliver completely clear skin, which is the driving ...